Short Interest in Mustang Bio, Inc. (NASDAQ:MBIO) Rises By 405.2%

Mustang Bio, Inc. (NASDAQ:MBIO) saw a large growth in short interest during the month of February. As of February 13th, there was short interest totaling 220,214 shares, a growth of 405.2% from the January 29th total of 43,589 shares. Currently, 3.1% of the company’s stock are short sold. Based on an average daily trading volume, of 771,653 shares, the short-interest ratio is currently 0.3 days. Based on an average daily trading volume, of 771,653 shares, the short-interest ratio is currently 0.3 days. Currently, 3.1% of the company’s stock are short sold.

Mustang Bio Stock Down 1.9%

MBIO opened at $1.01 on Friday. Mustang Bio has a 52 week low of $0.53 and a 52 week high of $7.00. The business’s 50 day moving average is $0.99 and its two-hundred day moving average is $1.29. The firm has a market cap of $7.37 million, a price-to-earnings ratio of -3.26 and a beta of 2.14.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Mustang Bio in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Mustang Bio presently has an average rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Mustang Bio stock. Kestra Advisory Services LLC lifted its holdings in shares of Mustang Bio, Inc. (NASDAQ:MBIO) by 68.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 111,042 shares of the company’s stock after buying an additional 44,934 shares during the period. Kestra Advisory Services LLC owned approximately 1.52% of Mustang Bio worth $109,000 at the end of the most recent quarter. 9.95% of the stock is owned by institutional investors.

About Mustang Bio

Mustang Bio, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies for oncology and rare genetic diseases. The company’s primary platform leverages chimeric antigen receptor T‐cell (CAR-T) technology to target both hematologic and solid tumor indications. In parallel, Mustang Bio is advancing a portfolio of lentiviral‐based gene therapy candidates designed to address inherited metabolic disorders with high unmet medical need.

The company’s oncology pipeline includes programs directed at B-cell malignancies and aggressive brain tumors, with lead CAR-T candidates in clinical trials for glioblastoma multiforme and various B-cell leukemias and lymphomas.